论文部分内容阅读
目的探讨螺内酯对实验性大鼠肝纤维化Ⅰ/Ⅲ型胶原蛋白表达的影响,初步揭示螺内酯对大鼠肝纤维化的预防作用及可能的机制.方法雄性 SD 大鼠81只,随机分为正常对照组(10只)、肝纤维化模型对照组(45只)及螺内酯组(26只).采用复合因素造模,螺内酯从造模开始每日1mL 100mg·kg~(-1)灌胃,共7wk.免疫组化染色及图像分析检测Ⅰ/Ⅲ型胶原含量.结果螺内酯组与肝纤维化组胶原面积比Ⅰ型胶原分别为:2.84±0.86,5.41±2.08,Ⅲ型胶原分别为:2.95±0.82,5.35±2.30.螺内酯组Ⅰ/Ⅲ型胶原增生程度明显降低(P<0.01).结论螺内酯可使肝组织Ⅰ/Ⅲ型胶原沉积明显减轻,提示螺内酯可明显预防肝纤维化的形成,ALD 在肝纤维化的发病中有一定意义.
Objective To investigate the effect of spironolactone on the expression of type Ⅰ / Ⅲ collagen in experimental rat hepatic fibrosis and preliminarily explore the preventive effect and possible mechanism of spironolactone on hepatic fibrosis in rats.Methods 81 male SD rats were randomly divided into normal Control group (n = 10), hepatic fibrosis model control group (n = 45) and spironolactone group (n = 26) .With compound factors, spironolactone was administered intragastrically at a dose of 100 mg · kg -1 A total of 7wk.Immunohistochemical staining and image analysis detection of type Ⅰ / Ⅲ collagen content.Results Spironolactone group and liver fibrosis collagen type area ratio of collagen I were: 2.84 ± 0.86,5.41 ± 2.08, Ⅲ collagen: 2.95 ± 0.82,5.35 ± 2.30. The level of type Ⅰ / Ⅲ collagen was significantly decreased in spironolactone group (P0.01) .Conclusion Spironolactone can significantly reduce the type Ⅰ / Ⅲ collagen deposition in liver tissue, suggesting that spironolactone can prevent the formation of hepatic fibrosis, ALD has a certain significance in the pathogenesis of liver fibrosis.